当前位置:首页 - 行情中心 - 华兰疫苗(301207) - 财务分析 - 资产负债表

华兰疫苗

(301207)

  

流通市值:33.67亿  总市值:143.28亿
流通股本:1.41亿   总股本:6.00亿

资产负债表

报告期2023-09-302023-06-302023-03-312022-12-31
公司类型通用通用通用通用
流动资产:
货币资金375,780,768.04734,259,178.99427,446,480.23600,041,864.54
应收票据及应收账款2,083,044,517.861,000,649,830.061,499,594,806.481,796,443,453.58
应收账款2,083,044,517.861,000,649,830.061,499,594,806.481,796,443,453.58
预付款项28,735,183.6624,930,223.2921,680,510.6120,220,435.82
其他应收款合计3,651,019.844,001,020.933,754,439.86411,023.39
存货291,551,265.8425,543,840.13321,355,281.16167,157,010.74
一年内到期的非流动资产371,298,083.33369,138,638.89130,000,000130,000,000
其他流动资产-15,930,189.741,870.3359,165,168.86
流动资产平衡项目0000
流动资产合计5,041,192,871.314,005,190,983.634,063,364,164.464,192,738,083.14
非流动资产:
固定资产1,204,003,175.411,227,968,080.071,260,265,910.391,283,020,368.71
在建工程3,297,915.223,297,915.223,297,915.223,257,484.22
生产性生物资产1,569,901.71349,001.83236,944.89647,588.06
无形资产20,289,410.3320,452,595.9320,615,781.5320,778,967.13
开发支出25,772,432.1725,021,768.8924,276,738.9624,164,435.79
长期待摊费用-1,473,300.073,001,574.024,529,847.97
递延所得税资产209,377,033.6200,276,678.94198,842,963.88208,560,107.56
其他非流动资产1,302,366,666.781,306,947,054.541,528,385,209.761,337,820,486.25
非流动资产平衡项目0000
非流动资产合计2,766,676,535.222,785,786,395.493,038,923,038.652,882,779,285.69
资产平衡项目0000
资产总计7,807,869,406.536,790,977,379.127,102,287,203.117,075,517,368.83
流动负债:
短期借款300,000,000300,000,000300,000,000300,183,333.33
应付票据及应付账款122,072,715.81135,215,845.08150,951,231.11125,670,056.81
其中:应付票据3,130,00018,512,44010,072,11015,313,310
应付账款118,942,715.81116,703,405.08140,879,121.11110,356,746.81
合同负债6,177,678.154,599,431.033,367,552.22,682,452.7
应付职工薪酬-3,542.67--
应交税费84,202,901.892,474,692.548,258,060.0812,894,924.81
其他应付款合计1,221,028,472.43805,419,611.09998,578,823.841,095,363,250.64
其他流动负债185,284.8137,843.79100,912.6379,973.93
流动负债平衡项目0000
流动负债合计1,733,667,053.081,247,850,966.21,461,256,579.861,536,873,992.22
非流动负债:
递延收益32,480,695.1633,539,238.8234,597,782.4835,656,326.14
递延所得税负债13,828,141.8210,390,538.258,686,916.486,410,721.02
非流动负债平衡项目0000
非流动负债合计46,308,836.9843,929,777.0743,284,698.9642,067,047.16
负债平衡项目0000
负债合计1,779,975,890.061,291,780,743.271,504,541,278.821,578,941,039.38
所有者权益(或股东权益):
实收资本(或股本)600,015,000600,015,000400,010,000400,010,000
资本公积2,910,232,165.782,903,030,382.63,095,833,599.423,088,631,816.24
盈余公积200,005,000200,005,000200,005,000200,005,000
未分配利润2,317,641,350.691,796,146,253.251,901,897,324.871,807,929,513.21
归属于母公司股东权益平衡项目0000
归属于母公司股东权益合计6,027,893,516.475,499,196,635.855,597,745,924.295,496,576,329.45
股东权益平衡项目0000
股东权益合计6,027,893,516.475,499,196,635.855,597,745,924.295,496,576,329.45
负债和股东权益合计7,807,869,406.536,790,977,379.127,102,287,203.117,075,517,368.83
公告日期2023-10-282023-08-242023-04-222023-03-30
审计意见(境内)标准无保留意见
TOP↑